Evidence mapPaperPMID 33794865Full record

Trial reportBMC pulmonary medicine2021

The effect of atorvastatin on inflammatory markers in sulfur mustard gas induced bronchitis: a randomized double-blinded, placebo-control clinical trial.

Behrooz Momeni, Saeed Nazer, Seyed Masoom Masoompour, Bita Geramizadeh, Seyed Vahid Sajadi

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Behrooz MomeniDepartment of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, 7193634154, Iran.
Saeed NazerStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Masoom MasoompourNon-Communicable Diseases Research Center, Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. masoomm@sums.ac.ir.ORCID http://orcid.org/0000-0002-0129-7155
Bita GeramizadehTransplant Research Center, Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Vahid SajadiDepartment of Emergency Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IR

Funding

Vice-Chancellor for Research, Shiraz University of Medical Sciences 7108
6 · The paper itself

Abstract

backgroundThis study was performed to evaluate the anti-inflammatory effect of atorvastatin in patients with chronic bronchitis, exposed to sulfur mustard gas.

methodsIn this randomized double-blinded clinical trial we recruited patients with chronic bronchitis after exposure to sulfur mustard gas. Ninety men 45-75 years old diagnosed with chronic bronchitis after exposure to mustard gas during the Iran-Iraq war, were randomly assigned to receive either atorvastatin (40 mg) or placebo once a day for 3 months. The interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), procalcitonin, highly sensitive CRP and COPD assessment test (CAT) score was compared at baseline and after 12 weeks.

resultsAfter consuming atorvastatin for 12 weeks, IL-6 level (mean difference [95%CI]; 0.2 [- 0.05, 0.5]), TNF-α (mean difference [95%CI]; - 0.07 [- 0.2, 0.07]), high sensitive CRP (mean difference [95%CI] - 0.1 [- 1.2, 0.9]), and procalcitonin (mean difference [95%CI]; 0.003 [- 0.02, 0.03]) did not change significantly. However, in the placebo group, only IL-6 (mean difference [95%CI]; 0.6 [0.2, 1.05]) decreased significantly after 12 weeks, but levels of high sensitive CRP (mean difference [95%CI]; - 0.3 [- 1.4, 0.8]) TNF-α (mean difference [95%CI]; - 0.2 [- 0.34, - 0.06]) and procalcitonin (mean difference [95%CI]; 0.02 [- 0.001, 0.04]) did not change significantly. After 12 weeks, the mean differences in TNF- α, IL-6 level, high sensitive CRP, procalcitonin, and CAT score did not significantly differ between the two groups.

conclusionsThe administration of 40 mg atorvastatin for 3 months did not significantly change the inflammatory markers or the quality of life of patients exposed to mustard gas with chronic bronchitis.

trial registrationIRCT, IRCT138904144312N1. Registered 16 August 2014, https://en.irct.ir/trial/4577 .

Indexed as

Quality of LifeAgedArmed ConflictsAtorvastatinBronchitis, ChronicC-Reactive ProteinDouble-Blind MethodHumansInflammation MediatorsInterleukin-6IranMaleMiddle AgedMustard GasProcalcitoninSeverity of Illness IndexAtorvastatinC-Reactive ProteinInflammation MediatorsInterleukin-6Mustard GasProcalcitoninTumor Necrosis Factor-alphaAtorvastatinChronic bronchitisStatinsSulfur mustard gas

Identifiers

PMID33794865
PMCPMC8017857
OpenAlexW3114745884

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.